Get the latest cancer news and research. Sort by cancer type or read the current headlines to learn what’s happening in the science of cancer detection and treatment, as well as healthy living tips for dealing with cancer.
12
U.S. scientists say they have discovered a group of genes that act as barriers against cancer development. Cold Spring Harbor Laboratory researchers said they used a powerful technology called RNA interference, which suppresses gene activity, to screen hundreds of candidate tumor suppressors in living mice, using small hairpin- shaped molecules that attach to specific genes and switch them off.
08
The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell transplantation remains an important therapeutic option for patients with multiple myeloma eligible for the procedure, scientists in the United States report.
According to recent research from the United States, Negative regulatory mechanisms within the solid tumor microenvironment inhibit antitumor T-cell function, leading to evasion from immune attack. One inhibitory mechanism is up-regulation of programmed death-ligand 1 (PD- L1) expressed on tumor or stromal cells which binds to programmed death-1 (PD-1) on activated T cells.
In this recently published study, investigators in the United States conducted a study To evaluate the patterns and timing of initial recurrence in patients with Hodgkin's lymphoma (HL) who subsequently underwent high-dose chemotherapy with autologous stem cell transplantation to enhance our understanding of the natural history of this disease and its modern treatment strategies and to direct approaches to disease surveillance.
01
The U.S. Food and Drug Administration has approved Folotyn (pralatrexate), the first treatment for a form of cancer known as Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkin's lymphoma.
Researchers detail in 'Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma,' new data in non-hodgkin lymphoma.
An investigative drug deprived non-Hodgkin lymphoma cells of their ability to survive too long and multiply too fast, according to an early study published recently in the journal Experimental Hematology.
25
24
Keryx Biopharmaceuticals, Inc. announced that KRX- 0401 (perifosine) has received Orphan-Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.
Genentech, Inc., a wholly-owned member of the Roche Group and Biogen Idec, announced that a Phase III study (PRIMA) showed that patients with follicular lymphoma who continued receiving Rituxan (rituximab) alone after responding to Rituxan and chemotherapy lived longer without their disease worsening (progression-free survival or PFS) than those who did not continue to receive Rituxan.
We care about your feedback. Let us know how we can improve your CancerCompass experience.